Exact Sciences Stock News

Exact Sciences Corporation (EXAS) CEO Kevin Conroy on Q4 2021 Results - Earnings Call Transcript

Exact Sciences press release (EXAS): Q4 GAAP EPS of -$1.28 misses by $0.44.Revenue of $473.81M (+1.6% Y/Y) beats by $26.25M.Shares -1%.FY 2022 Guidance: The company anticipates

MADISON, Wis., Feb. 22, 2022 /PRNewswire/ -- Exact Sciences Corp. (Nasdaq: EXAS), a leader in advanced cancer diagnostics, today announced that the company generated revenue of $473.8 million for the fourth quarter ended Dec. 31, 2021 and $1,767.1 million for the full year ended Dec. 31,

Exact Sciences (EXAS) delivered earnings and revenue surprises of -40.66% and 0.15%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Exact Sciences (NASDAQ:EXAS) is scheduled to announce Q4 earnings results on Tuesday, Feb. 22, after market close.The consensus EPS estimate is -$0.88

These investments seem pretty vulnerable right now.

These investments seem pretty vulnerable right now.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug A

Exact Sciences (EXAS) closed at $74.13 in the latest trading session, marking a -0.86% move from the prior day.

Cathie Wood's ARK Invest ETFs are some of the hottest funds after 2020's huge stock market gains.  The ARK Innovation ETF (NYSE: ARKK) grew more than 152% in 2020, beating the Nasdaq's 43.6% return.

RiverPark Funds, an investment management firm, published its “RiverPark Large Growth Fund” third quarter 2021 investor letter – a copy of which can be downloaded here.

Las Vegas, USA, Feb. 14, 2022 (GLOBE NEWSWIRE) -- Molecular Diagnostics Market is Expected to Grow at a Substantial CAGR of 9.21% and is Contemplated to Reach USD 16.12 Billion by 2026, Estimates DelveInsight Molecular Diagnostics Market is contemplated to witness huge demand in the upcoming years due to rising infectious diseases and their diagnosis, the presence of global as well as regional manufacturers active in developing the Molecular Diagnostic products such as Qiagen, Roche, Molbio Diagnostics Pvt. Ltd., among others. Also, improving healthcare infrastructure, government initiatives in raising awareness regarding molecular diagnosis will contribute to the Molecular Diagnostics market growth in these regions. DelveInsight''s Molecular Diagnostics Market Insights and Forecast report provides the current and forecast Molecular Diagnostics Market, upcoming innovation in the devices, individual market shares, challenges, drivers and barriers, market trends, and key competitors in the Molecular Diagnostics Market.

In the last trading session, 1.47 million shares of the Exact Sciences Corporation (NASDAQ:EXAS) were traded, and its beta was 1.18. Most recently the companys share price was $80.33, and it changed around -$1.16 or -1.42% from the last close, which brings the market valuation of the company to $13.48B. EXAS currently trades at a Why Exact Sciences Corporation (NASDAQ: EXAS) Stock Shouldnt Be Ignored In 2022 Read More »

Increase in number of orders for Cologuard and new study findings supporting the Oncotype DX are likely to have contributed to Exact Sciences' (EXAS) Q4 performance.